

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/852,547	05/10/2001	David A. Sirbasku	1944-00800	6474
23505	7590 10/02/2002	· ·		
CONLEY ROSE & TAYON, P.C.			EXAMINER	
P. O. BOX 326 HOUSTON, T	X 77253-3267		CANELLA,	KAREN A
			ART UNIT	PAPER NUMBER
			1642	2
			DATE MAILED: 10/02/2002.	フ

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No. 09/852,547

Applicant(s)

Sirbasku

Examiner

Karen Canella

Art Unit 1642

	The MAILING DATE of this communication appea	ars on the cover sheet with the correspondence address			
	for Reply				
THE	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.				
	sions of time may be available under the provisions of 37 CFR 1.136 (a). In a g date of this communication.	no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
- If the p - If NO p - Failure - Any re	period for reply specified above is less than thirty (30) days, a reply within th	and will expire SIX (6) MONTHS from the mailing date of this communication. he application to become ABANDONED (35 U.S.C. § 133).			
Status					
1) 🗆	Responsive to communication(s) filed on	·			
2a) 🗌	This action is FINAL. 2b) 💢 This action				
3) 🗆	closed in accordance with the practice under Ex pair	except for formal matters, prosecution as to the merits is arte Quayle, 1935 C.D. 11; 453 O.G. 213.			
-	ition of Claims				
4) 💢	Claim(s) <u>1-65</u>	is/are pending in the application.			
4	la) Of the above, claim(s)	is/are withdrawn from consideration.			
5) 🗆	Claim(s)	is/are allowed.			
6) 🗆	Claim(s)	is/are rejected.			
7) 🗆	Claim(s)	is/are objected to.			
8) 💢	Claims <u>1-65</u>	are subject to restriction and/or election requirement.			
Applica	ation Papers				
9) 🗆	The specification is objected to by the Examiner.				
10)	The drawing(s) filed on is/are	e a) \square accepted or b) \square objected to by the Examiner.			
	Applicant may not request that any objection to the di	rawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11)	The proposed drawing correction filed on	is: a) approved b) disapproved by the Examiner.			
	If approved, corrected drawings are required in reply t	to this Office action.			
12)	The oath or declaration is objected to by the Examin	ner.			
	under 35 U.S.C. §§ 119 and 120				
	13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
	☐ All b)☐ Some* c)☐ None of:				
	1. Certified copies of the priority documents have				
	2. Certified copies of the priority documents have				
	 Copies of the certified copies of the priority do application from the International Burea ee the attached detailed Office action for a list of the 				
		·			
_	 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). a) ☐ The translation of the foreign language provisional application has been received. 				
15)					
Attachm		Provide a construction of the construction of			
	ntice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).			
2) No	otice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)			
3) 🗌 Info	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:			



Art Unit: 1642

DETAILED ACTION

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-15 and 17-20, drawn to methods of predicting cancer susceptibility and methods of diagnosing cancer both methods comprising in vitro assays, classified in class 435, subclass 4.
 - II. Claim 16, drawn to a method of imaging a steroid hormone tumor in vivo, classified in class 424, subclass 9.1.
 - III. Claims 21-37, 39, 40, 42-45 and 47-52, drawn to methods of conferring resistance to, or suppressing malignancies, classified in, for example, class 514, subclass 12.
 - IV. Claim 41, drawn to a method of preparing an anti-cancer antibody, classified in class 424, subclass 184.1.
 - V. Claims 38 and 46, drawn to methods of detecting carcinogenic bacteria and methods for detecting infection, classified in class 435, subclass 5.
 - VI. Claims 53-60, drawn to compositions comprising immunoglobulin inhibitors, classified in class 530, subclass 300.
 - VII. Claims 61-64, drawn to expression vectors for gene replacement therapy, classified in class 514, subclass 44.
 - VIII. Claim 65, drawn to a method for treating breast cancer comprising administering an Fe(III) depleting substance and a Fe(III) containing substance, unclassifiable.
- 2. The inventions are distinct, each from the other because of the following reasons:

Inventions of Groups VI and VII are structurally and functionally different products which are made by different methods and have different uses. The examination of all groups would require different searches in the U.S. Patent Shoes and the scientific literature and would require the consideration of different patentability issues.

C & . . x . 9

The methods of Groups I-V and VIII differ in the method objectives, method steps and parameters and in the reagents used.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter and because the searches required for the groups are not co-extensive, restriction for examination purposes as indicated is proper.

- 3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Canella whose telephone number is (703) 308-8362. The examiner can normally be reached on Monday through Friday from 8:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Maren A. Canella, Ph.D.

Patent Examiner, Group 1642

October 1, 2002